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Abstract Cardiac toxicity is an uncommon but potentially seri-
ous complication of cancer therapy, especially with anthracy-
clines. One of the most e¡ective anticancer drugs is doxorubicin,
but its value is limited by the risk of developing cardiomyopathy
and ventricular arrhythmia. When applied to a network of peri-
odically contracting cardiomyocytes in culture, doxorubicin in-
duces rhythm disturbances. Using a novel rapid assay based on
non-invasive ion-conductance microscopy we show that the
L-antagonist esmolol can restore rhythm in doxorubicin-treated
cultures of cardiomyocytes. Moreover, esmolol pre-treatment
can protect the culture from doxorubicin-induced arrhythmia.
" 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Despite its well-documented cardiotoxic e¡ects, the anthra-
cycline antibiotic doxorubicin (adriamycin) remains a major
and most e¡ective anticancer agent against human malignan-
cies such as leukaemia, lymphomas and many solid tumours
[1]. Doxorubicin is also used in combination with other che-
motherapeutic agents (platinum and paclitaxel) for systemic
treatment of patients with endometrial cancer [2]. In prostate
cancer anthracyclines are often applied as a monotherapy or
in combination with other drugs [3]. However, chronic admin-
istration of doxorubicin produces a cumulative dose-depen-
dent and irreversible cardiac toxicity and arrhythmia [4] that
limits its optimum use. Wang showed electrocardiogram anal-
ysis of doxorubicin cardiac toxicity in 160 cancer cases. Many
patients displayed abnormal electrocardiograms [5]. Raabe
and Storstein reported that the number of ventricular extra-
systoles increased after doxorubicin infusion [6].
Cellular and molecular mechanisms of doxorubicin toxicity
are not fully understood. Available laboratory evidence sug-
gests that an increase in oxidative stress, brought about by
increased free radical production and decreased myocardial
endogenous antioxidants, plays an important role in the
pathogenesis of heart failure. Adriamycin-induced apoptosis
and hyperlipidaemia may also be involved in the process [7].
Esmolol is an ultra short-acting intravenous cardioselective
L-antagonist and it has been shown to produce a signi¢cant
dose-dependent decrease in ventricular rate [8]. Esmolol is
indicated in short-term treatment of hypertension and tachy-
cardia during the perioperative period and in clinical situa-
tions that require rapid L-receptor blockade [9]. The e⁄cacy
and safety of esmolol has been proven in speci¢c clinical set-
tings, i.e. in patients with hypertension, unstable angina, my-
ocardial infarction, and supraventricular tachyarrhythmias.
As esmolol’s antiarrhythmic action is at the level of the
L-adrenergic receptor, we hypothesised that it could be e¡ec-
tive in correction of doxorubicin-induced arrhythmia.
To study this possibility we chose a neonatal rat cardio-
myocyte culture. This culture provides a unique in vitro model
for studying drug e¡ects on the rhythm of cardiomyocyte
contraction. When cultured as a network, the early culture
consists of single myocytes, which exhibit unsynchronised
contraction. When any two spontaneously contracting neona-
tal myocytes establish contact, they synchronise. Subsequently
the cells proliferate, migrate and assemble into a monolayer
network that beats synchronously. Previously, Lampidis and
co-workers showed that doxorubicin produced arrhythmias in
cultures of neonatal rat cardiomyocytes [10]. Our doxorubi-
cin-related data discussed in the present paper and obtained
using a novel and rapid assay with a scanning ion conduc-
tance microscope [11] are in good agreement with this report.
2. Materials and methods
2.1. Preparation of a primary culture of neonatal rat cardiomyocytes
Ventricular myocytes were isolated from the hearts of 1^2 day old
rats [12]. Cells were kept in Dulbecco’s modi¢ed Eagle’s minimum
essential medium with 5% foetal calf serum (v/v), 200 Wg/ml strepto-
mycin, 200 U/ml penicillin, 5% (v/v) non-essential amino acids. Ge-
neticin (G418) at 50 Wg/ml was added to inhibit ¢broblast growth. (All
reagents are from Gibco, Paisley, UK.) Cells were maintained at 37‡C
in an atmosphere of humidi¢ed air plus 5% CO2. The density of
plating was 500 000 cells/ml. Cells were used following 3^4 days cul-
ture on glass coverslips (small network of cardiomyocytes).
2.2. Immunocytochemical detection of K-actinin
Cells were ¢xed with 4% formalin solution in phosphate-bu¡ered
saline (PBS), permeabilised with 0.1% Triton X-100 in PBS for 20 min,
blocking solution of 10% normal goat serum was applied, followed by
monoclonal antibodies to sarcomeric K-actinin, clone EA-53 (Sigma-
Aldrich, Poole, UK, A7811) in 1:100 dilution. The antigen was de-
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tected using £uorescein-conjugated secondary antibody. Slides were
observed under a Nikon-Eclipse TE300 microscope.
2.3. Drugs
A 100 Wg/ml stock solution of esmolol hydrochloride (Brevibloc,
Gensia Europe Ltd, Bracknell, UK) in Hanks’ balanced salt solution
bu¡er (Gibco) was prepared on the day of the experiment. Doxoru-
bicin (Sigma-Aldrich) was stored at 320‡C as a 250 Wg/ml stock so-
lution in Hanks’ balanced salt solution bu¡er. All drugs were diluted
to the desired concentrations in Hanks’ balanced salt solution bu¡er
on the day of the experiment.
2.4. E¡ect of drugs on amplitude and rhythm of contraction of
cardiomyocytes
To investigate the changes of the rhythm of cardiomyocyte contrac-
tion caused by the addition of drugs, we recorded the vertical cell
displacement of individual cells using a scanning ion conductance
microscope as described previously [11]. Fig. 1 shows our experimen-
tal setup. Brie£y, the sensitive probe of the scanning ion conductance
microscope is a glass micropipette, ¢lled with PBS solution. The
Ag/Cl electrode is plugged in to the pipette and connected to a current
ampli¢er to measure the ion current that £ows through the tip of the
micropipette. The current provides a feedback signal to move the
micropipette up and down, in order to keep the pipette^cell mem-
brane separation constant during contraction. Therefore, as the cell
surface rises during contraction, the micropipette is displaced verti-
cally (Z position in Fig. 1). This measurement allows alterations in
contraction to be recorded (inset).
3. Results
To establish the proportion of cardiomyocytes in the genet-
icin-treated cultures, cells were stained with antibodies to de-
tect sarcomeric K-actinin. Immunodetection showed that al-
most 80% of the cells possessed the myocyte marker, K-actinin
(Fig. 2).
Under control conditions, the cells beat regularly, with little
variation in rate as measured by recording the vertical cell
surface displacement of individual cells. We expressed the
rate as beat to beat interval to facilitate arrhythmia analysis.
This, clearly, also varied little and in each study beat to beat
intervals were consistent in each preparation ^ each roughly
near 3 s beat to beat interval. In this setting we applied doxo-
rubicin, alone or together with esmolol. Control 5 day old
cultures displayed regular contractions (Fig. 1, inset). In the
¢rst set of experiments (n=5) chronic addition of doxorubicin
in low doses (0.1 Wg/ml, every 48 h for 5 days) induced ar-
rhythmic activity. These rhythm irregularities included prema-
ture beats with compensatory pauses, sometimes with a bi-
geminal pattern (Fig. 3A). Fig. 3B shows the frequency
histogram of the inter-beat intervals. The S.D. is wide, re£ect-
ing the wide variation in inter-beat interval (arrhythmia).
Doxorubicin-treated cultures have beat intervals from 3 to
7 s and their S.D.s range from 1.4 to 3.9. The peak is di¡use
because the premature beats have a short interval, and they
are also associated with a long post-beat compensatory pause,
i.e. long interval. Having induced arrhythmia, we applied
1 Wg/ml esmolol acutely to these cultures. Esmolol restored
rhythmic contraction as shown in Fig. 3C. The histogram in
Fig. 3D has only one narrow peak ^ no bigemini and few, if
any, premature beats. The pattern in this representative ¢gure
was consistent, and was demonstrated in every experiment.
Esmolol-treated cultures have beat intervals from 1.4 to 2.2 s
and their S.D.s range from 0.3 to 0.7.
In the second set of experiments (n=6) a high dose of doxo-
rubicin (100 Wg/ml) given acutely caused arrhythmia in 5 day
old untreated cardiomyocytes with an occasional bigeminal
Fig. 1. A diagram of the experimental apparatus for recording of vertical displacement of the cell surface of a cardiomyocyte during contrac-
tion.
Fig. 2. Immunostaining of a cardiomyocyte cluster for cytoskeletal
proteins that are speci¢c to myocardium (K-actinin).
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pattern. The arrhythmia appeared as soon as 3^5 min after
doxorubicin addition (data not shown, but similar to data
shown in Fig. 3A). One hour later a severe arrhythmia was
evident in these cultures: the cells had prominent bigemini
(Fig. 4A). As in the previous set of experiments, the S.D.
was broad and there were two peaks re£ecting variable ar-
rhythmic inter-beat intervals, with an early peak for bigemini
(Fig. 4B). Doxorubicin-treated cultures have beat intervals
from 3 to 5 s and their S.D.s range from 1.8 to 3.0. Pre-
treatment with esmolol (1 Wg/ml) added 30 min before doxo-
rubicin addition prevented the arrhythmic e¡ect of the drug.
Even after 60 min of exposure to doxorubicin there were still
no disturbances of the rhythm of cardiomyocyte contraction
(Fig. 4C). The histogram now shows one peak (Fig. 4D).
Esmolol-pre-treated cultures have beat intervals from 2.0 to
2.8 s and their S.D.s range from 0.6 to 0.9.
4. Discussion
Neonatal rat cardiomyocyte cell culture has been developed
to address various aspects of myocardial physiology
[10,13,14]. Our assay, using this type of model, allowed us
to rapidly assess the action of drugs applied to a culture of
myocytes. Recordings of single living cell contractions in nor-
mal physiological solutions can be obtained in real time and
su⁄cient data for statistics can be quickly collected from the
same culture. Our assay has been used previously to show that
the time course of a cardiomyocyte contraction is commensu-
rate with its Ca2þ transient [11].
The cardiomyocyte culture model has some limitations
since it is based on a layer of not fully di¡erentiated cells.
Electrophysiologically they have no specialised pacemaker or
conducting cells as found in whole heart. Mechanically con-
traction is constrained due to attachment of the cells to the
surface on which they are cultured, and not constrained by
pressure or volume loads. However, it provides the advan-
tages of single cell study with the simultaneous convenience
of the manipulation and study of a two-dimensional network
of neighbouring cells synchronously contracting. In particular
its two-dimensional nature allows the application of di¡erent
microscopy techniques. Moreover, despite remarkable di¡er-
ences to whole heart, it can show arrhythmic behaviour, com-
mensurate in some respects with that in whole heart, in re-
sponse to arrhythmic and antiarrhythmic agents. A variety of
studies have therefore been performed on this model. For
instance, it has been possible for the ¢rst time to look at
the in£uence of the bile acid taurocholate on the function of
cardiomyocytes [15,16].
Previously the mechanism of doxorubicin cardiac toxicity
was shown to implicate Ca2þ homeostasis as a primary trig-
gering mechanism that leads to cardiomyopathy [17]. Maeda
et al. showed that ventricular rat cardiac myocytes treated
with doxorubicin exhibit signi¢cant changes in Ca2þ transi-
ents. The parameters of these Ca2þ transients showed strong
Fig. 3. Typical example of the e¡ect of esmolol on arrhythmia produced by chronic administration of low dose doxorubicin. A: Doxorubicin
induced rhythm disturbances, when added in low concentration (0.1 Wg/ml) over 5 days. B: Histogram of intervals of time between beats of
cardiac cell culture treated with doxorubicin at 0.1 Wg/ml over 5 days. Time of recording= 10 min. Time between all beats = 3.9 s, S 1.6
(meanSS.D.). N, number of intervals. C: Esmolol (1 Wg/ml) restored rhythm in doxorubicin-treated cultures. Measurement was taken 10 min
after addition of esmolol. D: A histogram of intervals of time between beats of cardiac cell culture treated with doxorubicin at 0.1 Wg/ml over
5 days after addition of esmolol (1 Wg/ml). Time of recording= 10 min. Time between beats = 2.0 s, S 0.4 (meanSS.D.). Note large S.D. in B
compared with D.
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L-adrenergic responsiveness [18]. Although the precise mech-
anisms of action and interactions of esmolol and doxorubicin
are largely unknown, we can speculatively implicate a L-adre-
noceptor responsiveness of the cardiomyocyte’s calcium tran-
sient parameters. There is a likely interaction between doxo-
rubicin toxicity and esmolol’s L-adrenergic blocking action.
Interestingly, esmolol has the e¡ect on a cultured myocyte
system where there are no catecholamines to block. A similar
non-catecholamine-blocking e¡ect was found for another
L-blocker, the L2adrenoceptor blocker ICI 118,551 in cardio-
myocytes. A Gi-dependent pathway was proposed for the
negative inotropic action of the L=blocker [19].
We conclude that in this model of cultured cardiomyocytes
esmolol pre-treatment can prevent doxorubicin arrhythmic
action and esmolol can also reverse doxorubicin-induced ar-
rhythmia. Moreover, although we did not study the molecular
mechanisms of the compounds under investigation, our stud-
ies strongly suggest that our simple non-animal model can be
used for investigation of individual arrhythmogenic drugs and
their interactions.
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